Compare EHang Holdings Ltd - ADR (EH) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EHang Holdings Ltd - ADR vs Inovio Pharmaceuticals Inc — how do they compare? EHang Holdings Ltd - ADR trades at $5.68 (market cap $437.63M), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: EHang Holdings Ltd - ADR is far larger — about 5.6× Inovio Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| EH | INO | |
|---|---|---|
Market Cap | $437.63M | $78.55M |
Sector | Industrials | Health |
52-Week High | $19.44 | $2.87 |
52-Week Low | $4.90 | $0.66 |
Enterprise Value | $376.84M | $49.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EHang Holdings (EH) trades at $5.79, up 1.76% today, with a mixed technical signal (bullish overall, bearish moving averages). The company reported Q1 2026 revenue of $418M, flat year-over-year, but net income margin remains deeply negative at -77.56%. Recent news includes the EH216-S completing Central Asia's first pilotless eVTOL flight in Kazakhstan (GlobeNewsWire, August 10, 2026), highlighting operational progress amid financial challenges.
Outlook is cautious; the stock faces significant execution risk with persistent losses and high cash burn, but analyst consensus price target of $6.97 offers modest upside. Investment opportunity hinges on successful commercialization of eVTOL technology, while risks include intense competition, regulatory hurdles, and reliance on financing to sustain operations.
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EHang Holdings Ltd - ADR
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
